TransMedics Operating Margin from 2010 to 2025
| TMDX Stock | USD 66.95 1.42 2.17% |
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 144.4 M or Research Development of 76.4 M, as well as many indicators such as Price To Sales Ratio of 11.6, Dividend Yield of 0.0 or PTB Ratio of 17.68. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
TransMedics | Operating Margin |
Latest TransMedics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of TransMedics Group over the last few years. It is TransMedics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.04 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
TransMedics Operating Margin Regression Statistics
| Arithmetic Mean | (1.22) | |
| Geometric Mean | 0.82 | |
| Coefficient Of Variation | (76.14) | |
| Mean Deviation | 0.57 | |
| Median | (1.25) | |
| Standard Deviation | 0.93 | |
| Sample Variance | 0.86 | |
| Range | 3.592 | |
| R-Value | 0.47 | |
| Mean Square Error | 0.71 | |
| R-Squared | 0.22 | |
| Significance | 0.06 | |
| Slope | 0.09 | |
| Total Sum of Squares | 12.88 |
TransMedics Operating Margin History
About TransMedics Financial Statements
TransMedics investors use historical fundamental indicators, such as TransMedics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company was founded in 1998 and is headquartered in Andover, Massachusetts. Transmedics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TransMedics Stock Analysis
When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.